

Ozgur Ozyilkan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1833003/publications.pdf>

Version: 2024-02-01

116
papers

5,371
citations

516561

16
h-index

88593

70
g-index

118
all docs

118
docs citations

118
times ranked

7044
citing authors

#	ARTICLE	IF	CITATIONS
1	nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR ⁺ , HER2 ⁻ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 55-64.		3
2	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2.	1.1	23
3	Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1623-1630.	0.5	0
4	Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). <i>Journal of Cancer Education</i> , 2020, 35, 69-75.	0.6	4
5	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. <i>Lung Cancer</i> , 2020, 148, 48-54.	0.9	18
6	2730 nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR ⁺ , HER2 ⁻ metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, S348.	0.6	4
7	Abstract P4-12-30: Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. , 2020, , .		0
8	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	5.1	418
9	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	6.3	1,804
10	<p>Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8807-8815.	0.9	19
11	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	6.3	2,347
12	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	0.6	78
13	P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey. <i>Journal of Thoracic Oncology</i> , 2019, 14, S558-S559.	0.5	3
14	Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR ⁺ , HER2 ⁻ advanced breast cancer. , 2019, , .		2
15	Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJ): Subgroup analysis from TAGS.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4037-4037.	0.8	5
16	Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1123-1132.	0.4	4
17	P1.17-02 Low Prognostic Nutritional Index Predicts Poor Survival in Stage IIIB Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, S655.	0.5	0
18	Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients. <i>Journal of Oncology</i> , 2018, 2018, 1-9.	0.6	4

#	ARTICLE	IF	CITATIONS
19	A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1223-1228.	1.0	3
20	Clinicohistopathological features and treatment outcomes in testicular lymphomas: A single center experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16533-e16533.	0.8	0
21	NÃ¶roendokrin tÃ¼mÃ¶rlerin klinikohistopatolojik Ã¶zellikleri ve tedavi sonuÃ§larÃ±: tek merkez deneyimi. <i>Cukurova Medical Journal</i> , 2018, 43, 533-538.	0.1	0
22	Flare Phenomenon in Advanced Colorectal Cancer: Cessation of Bevacizumab after Predefined Cycles of Therapy may not Affect Outcome.. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2017, 27, 53-59.	0.1	0
23	Characteristics of Turkish colorectal cancer patients and bevacizumab preference.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15055-e15055.	0.8	0
24	Outcomes of Turkish National Breast Cancer Registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12517-e12517.	0.8	1
25	An old enemy not to be forgotten during PET CT scanning of cancer patients: tuberculosis. <i>Wspolczesna Onkologia</i> , 2016, 2, 188-191.	0.7	1
26	110P: Predictive and prognostic role of T-regulatory cells in resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S103-S104.	0.5	1
27	Evaluation of flare phenomena in advanced colorectal cancer after bevacizumab cessation in the well-responded cases.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15019-e15019.	0.8	0
28	Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases. <i>Molecular and Clinical Oncology</i> , 2015, 3, 400-402.	0.4	4
29	Prognostic Role of T-Regulatory Cells in Completely Resected Early Stage Non-Small Cell Lung Carcinoma. <i>Annals of Oncology</i> , 2015, 26, i18.	0.6	0
30	Procalcitonin as a biomarker for infection-related mortality in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 168-173.	0.5	9
31	Multifocal soft tissue Langerhansâ€™ cell histiocytosis treated with PET-CT based conformal radiotherapy. <i>Japanese Journal of Radiology</i> , 2015, 33, 603-606.	1.0	1
32	P352 A puzzle for breast surgeons: type and timing of the surgery for metastatic breast cancer. <i>Breast</i> , 2015, 24, S148.	0.9	0
33	Perspectives and practical applications of medical oncologists on defensive medicine (SYSIPHUS) Tj ETQq1 1 0.784314 rgBT /Overlock <i>Medical Oncology</i> , 2015, 32, 106.	1.2	7
34	The Perspective of Non-oncologist Physicians on Patients with Metastatic Cancer and Palliative Care (ALONE Study): A Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). <i>Journal of Cancer Education</i> , 2015, 30, 253-259.	0.6	7
35	Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?. <i>Medical Oncology</i> , 2015, 32, 476.	1.2	4
36	Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center Experience. <i>Medical Science Monitor</i> , 2015, 21, 661-666.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.4	24
38	Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12656-e12656.	0.8	0
39	Can primary tumor localization predict the which patient will have benefit from addition of taxanes to platin-5-FU based regimens in metastatic gastric cancer. Multi center retrospective analysis from Turkey, Society of Turkish Oncology Group study.. Journal of Clinical Oncology, 2015, 33, e15030-e15030.	0.8	0
40	Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12653-e12653.	0.8	0
41	Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12657-e12657.	0.8	0
42	Turkish National Breast Cancer Registry.. Journal of Clinical Oncology, 2015, 33, e12654-e12654.	0.8	0
43	Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study. Medical Oncology, 2014, 31, 350.	1.2	2
44	Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. International Urology and Nephrology, 2014, 46, 1531-1535.	0.6	21
45	Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?. Medical Science Monitor, 2014, 20, 428-433.	0.5	4
46	Malignant pleural mesothelioma: A single-center experience in Turkey. Medical Science Monitor, 2014, 20, 825-832.	0.5	4
47	Primary Extranodal Non-Hodgkin's Lymphoma: Clinicopathological Features, Survival and Treatment Outcome in Two Cancer Centers of Southern Turkey. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7207-7211.	0.5	5
48	Lack of Prognostic Significance of C-erbB-2 Expression in Low- and High- grade Astrocytomas. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1333-1337.	0.5	5
49	Investigational tests and treatments performed in terminal-stage cancer patients in two weeks before death: Supportive care study group in Turkish Oncology Association.. Journal of Clinical Oncology, 2014, 32, e20503-e20503.	0.8	0
50	Scleroderma after 5-fluorouracil and folinic acid therapy in a patient with colon carcinoma. Ąukurova Ąeniversitesi TĄp FakĄltesi Dergisi, 2014, 39, .	0.0	0
51	Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors. Supportive Care in Cancer, 2013, 21, 1131-1135.	1.0	5
52	Does Fascin Expression in Diffuse Large B-Cell Lymphomas have a Clinical Impact in Patients Treated with Anthracyclin-Based Chemotherapy Plus Rituximab?. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2013, , 73-78.	0.1	1
53	Oncologic Treatment of Non-Small Cell Lung Cancer Part A: Neoadjuvant Chemotherapy Options for Non-Small Cell Lung Carcinoma. , 2013, , 365-370.		0
54	Oncologic Treatment of Non-Small Cell Lung Cancer Part B: Adjuvant Chemotherapy for Resected Non-Small Cell Lung Carcinoma. , 2013, , 371-376.		0

#	ARTICLE	IF	CITATIONS
55	Successful Treatment of Aortic Rupture with Endovascular Stent Grafting in a Patient with Mantle Cell Lymphoma. Case Reports in Oncology, 2012, 5, 275-279.	0.3	3
56	Effectiveness of percutaneous metal stent placement in cholangiocarcinoma patients with midterm follow-up: Single center experience. European Journal of Radiology, 2012, 81, 1724-1727.	1.2	7
57	Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study. Medical Oncology, 2012, 29, 3608-3613.	1.2	10
58	Timing and Patterns of Disease Progression Following Concurrent Radiochemotherapy in Patients with Unresectable Locally-Advanced Pancreas Cancer. Annals of Oncology, 2012, 23, ix238.	0.6	0
59	Outcomes of Aggressive Concurrent Chemotherapy in Septuagenarians with Stage IIIB Non-Small Cell Lung Carcinoma. Annals of Oncology, 2012, 23, ix392.	0.6	0
60	Definitive Thoracic Chemoradiotherapy in Non-Small Cell Lung Cancer Patients with Solitary Brain Metastasis. Annals of Oncology, 2012, 23, ix424.	0.6	0
61	Weight Loss Despite Oral Glutamine Supplementation Predicts Poor Prognosis in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. Annals of Oncology, 2012, 23, ix520-ix521.	0.6	1
62	Role of Vitamin D3 in Prevention of Radiotherapy-Induced Epiphyseal Injury. Annals of Oncology, 2012, 23, ix526.	0.6	0
63	Does FDG-PET-CT based Re-Staging Influences Initial Management Decision and Clinical Outcome in Patients with locally advanced Pancreatic Carcinoma Planned to Undergo Chemoradiotherapy?. Annals of Oncology, 2012, 23, ix237.	0.6	0
64	Effect of Zoledronic Acid Used Concurrently with Radiation Therapy on Growth of Bone Epiphyseal Plaque. Annals of Oncology, 2012, 23, ix526.	0.6	0
65	A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit. Oral Oncology, 2012, 48, e2-e3.	0.8	37
66	Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer, 2011, 71, 109-112.	0.9	29
67	Hypertension Associated With Angiogenesis Inhibitors: What Do Oncologists Really Do in Daily Routine? A Small Survey. Journal of Clinical Hypertension, 2011, 13, 863-863.	1.0	1
68	Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: Baskent University experience.. Journal of Clinical Oncology, 2011, 29, e16001-e16001.	0.8	3
69	The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.. Journal of Clinical Oncology, 2011, 29, e19598-e19598.	0.8	1
70	Signet-ring cell carcinoma of the colon with leptomeningeal involvement. Journal of Clinical Neuroscience, 2010, 17, 1051-1053.	0.8	7
71	Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutaneous and Ocular Toxicology, 2010, 29, 140-142.	0.5	20
72	Hepatotoxicity and Hepatic Dysfunction. , 2010, , 267-278.		1

#	ARTICLE	IF	CITATIONS
73	Cisplatin combination regimen in the second-line treatment of non-small cell lung cancer.. Journal of Clinical Oncology, 2010, 28, e18136-e18136.	0.8	0
74	CA 15-3, Ceruloplasmin and tissue polypeptide specific antigen as a tumour marker panel in breast cancer. East African Medical Journal, 2009, 77, 291-4.	0.0	1
75	Primary Renal Lymphoma: Report of Four Cases. Oncology Research and Treatment, 2009, 32, 200-202.	0.8	18
76	Squamous cell carcinoma of the renal pelvis. Medical Oncology, 2009, 26, 103-104.	1.2	8
77	The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Journal of Experimental and Clinical Cancer Research, 2009, 28, 97.	3.5	21
78	Little dose, huge toxicity: profound hematological toxicity of intrathecal methotrexate. Leukemia and Lymphoma, 2009, 50, 282-283.	0.6	7
79	Signet-ring cell carcinoma of the gallbladder: a case report. Advances in Therapy, 2008, 25, 520-523.	1.3	25
80	Colon Adenocarcinoma and Solitary Tibia Metastasis: Rare Entity. Journal of Gastrointestinal Cancer, 2008, 39, 146-148.	0.6	9
81	Prostate Small Cell Carcinoma and Skin Metastases: A Rare Entity. Medical Principles and Practice, 2008, 17, 250-252.	1.1	12
82	Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8. Tumori, 2008, 94, 474-480.	0.6	7
83	Role of c-erbB2 expression in non-small cell lung cancer. Journal of Clinical Oncology, 2008, 26, 22044-22044.	0.8	0
84	Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8. Tumori, 2008, 94, 474-80.	0.6	4
85	Drug interaction between capecitabine and warfarin: a case report and review of the literature. International Journal of Clinical Pharmacology and Therapeutics, 2006, 44, 80-82.	0.3	14
86	MALTOMA Presenting With Thrombocytopenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 321-322.	0.6	6
87	Multiple Myeloma With Pleural Involvement. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 429-430.	0.6	13
88	Primary Squamous Cell Carcinoma of the Stomach a Case Report. Tumori, 2005, 91, 440-442.	0.6	10
89	Controversy in Folinic Acid Administration After Fluorouracil. Journal of Clinical Oncology, 2005, 23, 3862-3862.	0.8	0
90	Prognostically Favorable Abdominal Breast Cancer Metastases with Stomach Involvement. Oncology Research and Treatment, 2005, 28, 270-272.	0.8	4

#	ARTICLE	IF	CITATIONS
91	Hodgkin's disease in an elderly patient with B-Cell chronic lymphocytic leukemia. Indian Journal of Cancer, 2005, 42, 158.	0.2	4
92	Primary thyroid lymphoma: report of two cases. East African Medical Journal, 2004, 81, 378-80.	0.0	4
93	Metastatic Cerebellar Medulloblastoma in the Liver Mimicking a Complicated Cyst: Sonographic and MDCT Findings. American Journal of Roentgenology, 2004, 183, 1608-1610.	1.0	0
94	Acute Interstitial Pneumopathy Associated with Docetaxel Hypersensitivity. Oncology Research and Treatment, 2004, 27, 563-565.	0.8	10
95	Acute Myeloid Leukemia 4 Years After Kaposi's Sarcoma in a Renal Transplant Recipient. Oncology Research and Treatment, 2004, 27, 163-165.	0.8	3
96	Appendicular Metastasis From Pancreatic Adenocarcinoma. International Journal of Gastrointestinal Cancer, 2004, 34, 55-58.	0.4	15
97	Olive-oil consumption and cancer risk. European Journal of Clinical Nutrition, 2003, 57, 191-191.	1.3	23
98	Treatment results in renal transplant recipients with non-Hodgkin's lymphoma. Transplantation Proceedings, 2003, 35, 1404-1407.	0.3	2
99	ESMO takes a stand on supportive and palliative care. Annals of Oncology, 2003, 14, 1335-1337.	0.6	99
100	Cost-Effectiveness of Chemotherapy in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 3750-3752.	0.8	4
101	Adenocarcinoma of the Lung in a 32-Year-Old Man: Is It Worthwhile to Check for Lung Cancer in Young Adults?. Oncology Research and Treatment, 2002, 25, 64-64.	0.8	2
102	Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma. Cancer, 2002, 94, 282-282.	2.0	0
103	Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer, 2002, 95, 2038-2039.	2.0	0
104	Tamoxifen-Induced Cirrhotic Process. Breast Journal, 2001, 7, 442-443.	0.4	5
105	A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin. American Journal of Gastroenterology, 2000, 95, 1093-1094.	0.2	15
106	Gastric Hodgkin's Disease Presenting With Radiological Appearance of Linitis Plastica. American Journal of Gastroenterology, 1999, 94, 3661-3662.	0.2	0
107	Gastric Hodgkin's disease presenting with radiological appearance of linitis plastica. American Journal of Gastroenterology, 1999, 94, 3661-3662.	0.2	1
108	Imipenem - Cilastatin versus Sulbactam - Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients. Korean Journal of Internal Medicine, 1999, 14, 15-19.	0.7	16

#	ARTICLE	IF	CITATIONS
109	Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas. <i>European Journal of Cancer</i> , 1998, 34, 759-760.	1.3	1
110	Haemostatic Changes; Plasma Levels of Alpha2-Antiplasmin-Plasmin Complex and Thrombin-Antithrombin III Complex in Female Breast Cancer. <i>Tumori</i> , 1998, 84, 364-367.	0.6	19
111	VB-CHOP chemotherapy regimen for aggressive non-Hodgkin's lymphomas. <i>European Journal of Haematology</i> , 1998, 61, 261-265.	1.1	3
112	The correlation between p53 tumor suppressor gene and proliferating cell nuclear antigen expressions in colorectal adenocarcinoma. <i>Pathology International</i> , 1995, 45, 973-974.	0.6	3
113	Prevalence of hepatitis C, B and D markers in cancer patients in Turkey. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1994, 13, 38-40.	1.3	3
114	Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Td 2002-2003.	2.0	4
115	Intrapleural and intraperitoneal palliative treatment of malignant effusions with mitoxantrone. <i>Anti-Cancer Drugs</i> , 1993, 4, 98-99.	0.7	0
116	Superior Vena Cava Syndrome: Experience at the Hacettepe Medical Center. <i>Annals of Saudi Medicine</i> , 1992, 12, 587-589.	0.5	0